🇺🇸 FDA

Company profile · Sponsor

Aspire

Aspire Biopharma Holdings

ASBP · NYSE biotech ESTERO, FL, USA
Pipeline
8
Drugs
0
Patents
1

Quick answer

Aspire (ASBP) is a biotech company. headquartered in ESTERO, FL, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 1 patent to this profile..

Company facts

Ticker ASBP
Exchange NYSE
Company type biotech
Headquarters ESTERO, FL, USA
SEC CIK 0001847345

Pipeline (8)

Search pipeline →

  1. ACT-20-MSC

    Aspire

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  2. Retinol

    Aspire

    Bronchopulmonary Dysplasia

    phase 2 small molecule active

    1 trial

  3. AdreView

    Aspire

    Heart Failure

    approved small molecule completed

    1 trial

  4. Myocardial perfusion imaging

    Aspire

    Coronary Artery Disease

    approved other completed

    1 trial

  5. Pulse Sequence

    Aspire

    Atrial Fibrillation

    approved other completed

    1 trial

  6. Regadenoson

    Aspire

    Coronary Artery Disease

    approved small molecule completed

    1 trial

  7. Beet It Sport Shot

    Aspire

    Blood Pressure

    other completed

    1 trial

  8. Nutritional Supplement

    Aspire

    Healthy

    other completed

    1 trial

Patents (1)

Search patents →

  1. US 10350296

    Chewable gelatin formulations

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Aspire?

Aspire (ASBP) is a biotech company. headquartered in ESTERO, FL, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 1 patent to this profile..

What pipeline programs does Aspire sponsor?

We track 8 ClinicalTrials.gov-linked programs for Aspire, including ACT-20-MSC and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Aspire company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.